# Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

> **NCT03955445** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 225 (estimated)

## Conditions studied

- C3 Glomerulopathy
- Immune-complex-membranoproliferative Glomerulonephritis

## Interventions

- **DRUG:** LNP023

## Key facts

- **NCT ID:** NCT03955445
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-03
- **Primary completion:** 2036-05-30
- **Final completion:** 2036-05-30
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03955445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03955445, "Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03955445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*